Evidence map›Paper›PMID 35489184›Full record

ArticleJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association2022

The Effects of COVID-19 on Patients with Acute Ischemic and Hemorrhagic Stroke.

Hesamodin Ashrafian Amiri, Athena Sharifi Razavi, Nasim Tabrizi, Hamed Cheraghmakani, Seyed Mohammad Baghbanian, Mehraz Sedaghat-Chaijan, Ashraf Zarvani, Monireh Ghazaeian, Abolfazl Hosseinnataj

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hesamodin Ashrafian AmiriDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Iran.
Athena Sharifi RazaviDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Nasim TabriziDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Hamed CheraghmakaniDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Seyed Mohammad BaghbanianDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mehraz Sedaghat-ChaijanDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Iran.
Ashraf ZarvaniDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Monireh GhazaeianDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: ghazaeianm@gmail.com.
Abolfazl HosseinnatajDepartment of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to evaluate how COVID-19 affects patients with acute ischemic or hemorrhagic stroke outcome. MATERIALS AND

methodsThis retrospective study was performed on adult patients (> 18 years old) with stroke (ischemic or hemorrhagic) who were admitted to hospital with or without COVID-19. The primary outcome was stroke-related disability, which was measured by mRS at baseline and discharge. Hospital duration, intensive care unit (ICU) admission, and mortality were considered the secondary outcomes.

resultsFrom February 2019 until August 2020, we recruited and analyzed 151 patients, 42 of whom had COVID-19 based on RT-PCR tests or lung CT scan findings. COVID-19 positive patients had higher baseline and final mRS scores than the control group (4.46 ± 0.67 vs 4.79 ± 0.61, P: 0.001, 3.83 ± 1.22 vs 4.46 ± 0.67, P: 0.001). Moreover, stroke patients with COVID-19 experienced a more severe disease and required a higher rate of ICU admission (17 vs 0, P:0.001) and longer hospitalization compared to those without COVID-19 (8.50 ± 7.86 vs 7.5 ± 11.20, P: 0.021). Also, mortality was higher in the COVID-19 group (19 vs 13, P:0.001). There was not any significant differences between the two groups in terms of the involvement of cerebral arteries and type of stroke. Male sex, COVID-19, and ICU admission were the main independent risk factors for death.

conclusionThe results of the study showed stroke patients (ischemic or hemorrhagic) with COVID-19 can have more disabilities and incur more hospital complications and mortality than non-COVID-19 patients.

Indexed as

COVID-19Hemorrhagic StrokeStrokeAdolescentAdultHospitalizationHumansMaleRetrospective StudiesRisk FactorsCOVID-19Hemorrhagic strokeIschemic strokeOutcome

Identifiers

PMID35489184
PMCPMC9015955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.